PRNewsWire
08 Jul 2026, 00:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri Trial failed to achieve its primary endpoint regarding the reduction of late-stage cancer diagnoses. — Failure of a primary clinical trial for a core product typically leads to a massive loss in valuation and undermines the company's commercial viability.
-0.90GRAIL is facing a securities class action lawsuit alleging it misled investors regarding the design and likely success of the NHS-Galleri trial. — Legal challenges and allegations of securities fraud create additional financial liabilities and reputational damage beyond the clinical failure.
-0.40The market responded to the trial failure with a share price drop of over 50% and a loss of $2.2 billion in market capitalization. — This confirms the immediate and severe negative market consensus on the company's current valuation.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company faced a $2.2 billion market cap loss, a failed clinical trial, and a securities class action lawsuit.
The company is facing a securities class action lawsuit related to IPO disclosures.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
